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Abstract 
 
N, N-dimethyltryptamine (DMT) is an indole alkaloid produced by a number of plants and animals, 
including humans. Its psychoactive effects were first described in 1956 by Stephen Szára, but have been 
exploited for centuries by South American indigenous populations throught the use of ayahuasca, an infusion 
made with a mixture of plants rich in the psychadelic DMT. In the present review, we assess the state of the 
art regarding a putative role for endogenous DMT and potential future clinical applications. We gathered 
papers published until 20 March 2018 and included in the PubMed database using the words: N,N-
dimethyltryptamine and ayahuasca. While the role of endogenous DMT remains unclear, ayahuasca has 
promising results in anxiety, depression and substance dependence. Thus, we conclude that although little 
has been proven, much has been speculated about the endogenous role of DMT. Overcoming the 
methodological setbacks is crucial to develop research further. In the other hand, ayahuasca has a good safety 
profile and growing evidence it could be used in therapy for some neuropsychiatric diseases. 
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 Introduction 
 
N,N-dimethyltryptamine (DMT) is an indole alkaloid widely found in nature. It is an endogenous 
compound in animals and in a extensive variety of plants around the globe1. DMT can be produced in the 
human body, in very small quantities 2 and is also produced by rats 3. This presence across species may 
suggest that it has an important biological role conserved throughout the evolution, or that it is a remnant of 
a biological function that has fallen into disuse. When administered exogenously, due to its hallucinogenic 
properties, DMT has been used to study “outside the body” experiences and dreams, while also being used 
as a model for psychosis 4,5.  
The exogenous administration of DMT is mostly associated with ayahuasca, which is a psychotropic 
plant tea traditionally used for centuries by indigenous and shamanists of Amazonian countries such as 
Brazil, Colombia, Peru, and Ecuador for magical- religious and therapeutic purposes. However, in the last 
25 years, ritual and therapeutic use of Ayahuasca has spread from small cities in the Amazonian jungle to 
the urban centers across the world 6. 
Ayahuasca is usually obtained by boiling the leaves of the bush Psychotria viridis (known as 
chacrona or queen), rich in DMT, and stalks of the vine Banisteriopsis caapi which contains β-carboline 
alkaloids such as harmine, tetrahydroharmine and harmaline, that are reversible inhibitors of monoamine 
oxidase A (MAO-A). DMT is a substrate for MAO-A, so it is rapidly metabolized, failing to produce the 
known effects if administered without an inhibitor of this enzyme1. 
While research on pure DMT has focused on the basic physiological effects and psychotomimesis of 
DMT which is essential for understanding its endogenous role, the rapid growth of ayahuasca as a cultural 
phenomenon and religious sacrament has ignited curiosity about its exogenous effects. Indeed, as the 
research on dissociative drugs such as psilocybin has been of increasing importance in the affective spectrum 
pathology7 the therapeutic potential of ayahuasca has been rising and bringing promising results8. 
 The present literature review aims to situate the research on the endogenous role of DMT, as well as 
to point out the therapeutic potential based on the research with ayahuasca. 
 
 
 
 
N,N-dimethyltryptamine 
 
Pharmacology 
 
• Pharmacokinetics  
A review by Barker in 2012 evaluated 69 studies reporting the detection of claimed endogenous 
hallucinogens DMT; 5-hydroxy-DMT (HDMT, bufotenine); 5-methoxy-DMT (MDMT) in humans and 
concluded that exists evidence support for the confirmation of their presence in certain human biological 
fluids [cerebrospinal fluid (CSF; DMT and MDMT), blood (DMT and HDMT) and urine (DMT and 
HDMT)]. To assess the possible origin of these substances, the same group used liquid chromatography-
tandem mass spectrometry (LC/MS/MS) to analyze micro-dialysates from the rat pineal gland, showing the 
presence of DMT2,3. DMT may be produced in different tissues, but due to the methodological inability to 
directly detect it and to its small endogenous production, more studies need to be performed.  
 Given these issues, exogenous DMT was used in studies to clarify its kinetics. DMT is synthesized 
by decarboxylation to tryptamine of the essential amino acid tryptophan. Tryptamine is then transmethylated 
by the indolethylamine-N-methyltransferase (INMT) enzyme (using S-adenosyl methionine as a substrate), 
which catalyzes the addition of methyl groups resulting in the production of N-methyltryptamine (NMT) 
and DMT. NMT can also act as a substrate for INMT-dependent DMT biosynthesis. INMT is widely 
expressed in the body, primarily in peripheral tissue such as the lungs, thyroid and adrenal gland. INMT is 
located in intermediate levels in placenta, skeletal muscle, heart, small intestine, stomach, retina, pancreas, 
and lymph nodes. It is densely located in the anterior horn of the spinal cord. Within the human brain, the 
highest INMT activity has been found in the uncus, medulla, amygdala, frontal cortex, and in the fronto-
parietal and temporal lobes. Further, Cozzi et al. (2011)1 demonstrated INMT expression in the pineal gland 
as well2. Nonetheless, given that there are other substrates for INNT, its expression does not reflect presence 
of DMT9. 
DMT is not active when oral administrated, probably due to its rapid degradation by MAO enzyme 
which catalyzes the oxidation of biogenic amines. Ayahuasca contains the carboline alkaloids harmine, 
harmaline and tetrahydro-harmine, that are potent MAO inhibitors, preventing the first-pass oxidative 
deamination of DMT. DMT can act as monoamine oxidase inhibitor at high doses (maximum effects at 50 
mg/kg), and is selective for MAO-A. In the rat brain, proniazid (MAO-A inhibitor) extends the half-life of 
DMT1. 
None of the metabolites produced DMT-like effects in both human and rodent models. From the 
MAO pathway are produced several molecules: NMT, 6-hydroxy-DMT (6-OH-DMT), 6-OH-DMT-N-oxide 
(6-OH-DMT-NO), DMT-N-oxide (DMT-NO), and indole-3-acetic acid (IAA). The major metabolites are 
DMT-NO, and IAA. In the rabbit liver, all five compounds were found, however, in the rabbit brain no 6-
OH metabolites were identified. Since a small fraction of exogenous DMT is excreted in urine unchanged 
despite taken with MAO inhibitors1, it is possible that oxidative deamination of DMT by MAO is not the 
exclusive metabolic pathway in humans. 
The subjective effects of intravenous administration of DMT (typical dose 0.1 – 0.4 mg/kg;) reach 
to maximum at about 5 min and disappear by 30 min. Intramuscular effects of DMT hydrochloride or DMT 
fumarate (reported dose 0.2- 1 mg/kg;) have a quick incipience within 2 – 5 min and can last 30 - 60 min, 
the effects are generally weaker than intravenous or inhalation route. Per os, the hallucinogenic effects of 
DMT in the formulation of ayahuasca, which contains MAO inhibitors (0.6 - 0.85 mg/kg DMT), generally 
have an onset within 60 min, peak at 90 min and can remain for approximately 4h. The typical doses of 
smoked or inhaled free-base DMT are 40 - 50 mg, although dose may be as high as 100mg. The effect of 
these doses of smoked DMT is rapid, similar to that of intravenous administration, but lasts less than 30 min. 
Intranasal free-base DMT was inactive (0.07 – 0.28 mg/kg), as was DMT administered rectally (1.7 mg/kg) 
of the bioxalate salt1. 
 
• Pharmacodynamics 
DMT orally ingested via ayahuasca produces neurochemical and behavioral effects, such as 
sympathomimetic effects, decreases in motor activity, impairment of cognitive function, raise of prolactin 
and cortisol levels, and reduction of lymphocytes1. 
 In humans, chronic use of ayahuasca may change brain structure, correlating with increased thinning of 
the posterior cingulate cortex, though not showing increased psychopathology or worse neuropsychological 
performance in the users10.  
Although little or no tolerance develops to the subjective effects, several early studies demonstrated that 
tolerance can be developed peripheral effects, namely cardiovascular, with DMT administration1. 
 
Molecular Targets 
 
The action mechanisms for psychedelics are currently not all clear, but most studies focus on DMT 
as a partial agonist of serotonin (5-HT) receptors. 5-HT2A receptor is pointed to be the main target of classic 
serotonergic-mediated psychedelic compounds, but also not sufficient for hallucinogenic effects and 5- 
HT2C and 5-HT1A receptors may play important roles as well11. Two other receptors have been investigated 
as possible targets for DMT, the trace amine receptor (TAAR) family and sigma-1 receptors (S1R). Here we 
will provide a description of the studies conducted with these receptors. 
 
• 5-HT2 
The known subjective effects of DMT have been attributed essentially to the 5-HT receptors12, 
already widely used with affinity for other psychedelic receptors, the best described are 1A, 2A, and 2C 
receptor subtypes, with focus at 5-HT2A receptors. DMT binds all 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-
HT2B, 5-HT2C, 5-HT5A, 5-HT6 and 5-HT7 receptors with affinities (Ki) between 39 nM to 2.1 µM13. The 
inhibition coefficient (Ki) of DMT at the human 5-HT2A receptor is reported as 130 nM13. DMT acts as 
agonist at the 5-HT1A and 5HT2C receptors as well. 
Like other classic psychedelics, DMT increases 5-HT levels and/or decrease its turnover. Moreover, 
doses of ayahuasca 15 or 30-fold higher than usually used ritual doses increased serotonergic 
neurotransmission. Although DMT inhibited 5-HT transport with a Ki of 4 µM at the serotonin reuptake 
transporter (SERT), there are no conclusions about the mechanism of interaction. As happens with 
amphetamine derivatives such as para-chloroamphetamine (pCA) and MDMA, SERT can be induced to 
operate in the reverse direction by SERT substrates, including 5-HT and tyramine. Blough et al. (2014)14 
found that DMT was a SERT ligand, with an EC50 value of 114 nM. The most probable mechanism is DMT-
induced release of neuronal 5-HT, in a way similar to that of amphetamines such as MDMA15. 
 
• Sigma-1 
The sigma receptor was originally proposed as a subtype of opioid receptors, but later studies 
confirmed them as non-opioid receptors playing a more diverse role in intracellular signaling, apoptosis and 
metabolic regulation16. 
Sigma-1 receptors are intracellular receptors acting as chaperone proteins that modulate Ca2+ 
signaling through the IP3 receptor. S1Rs and ion channels may play an important role in neuroplasticity 
processes, resulting in the need for lower doses to reach therapeutic concentrations. Of particular interest is 
the non-linear dose response curve of S1R agonists in in vitro experiments, in which S1R agonists are active, 
 e.g. learning and memory processes, depression and anxiety. The S1R, at the mitochondrial-associated 
endoplasmic reticulum membrane, is responsible for mitochondrial metabolic regulation and promotes 
mitochondrial energy depletion and apoptosis. Studies have demonstrated that they play a role as a modulator 
of ion channels and regulate lipid transport and metabolism, neuritogenesis, cellular differentiation and 
myelination in the brain. S1R polymorphism is associated with an increased risk of schizophrenia and 
differential activation of the prefrontal cortex and the severity of Alzheimer’s. S1R antagonists show 
antipsychotic effects in vivo15,16. 
Given that steroids bind to sigma receptors, it is possible that it serves as a link among endocrine, 
nervous, lung, kidney, heart, intestines, liver, sexual and immune systems; S1R are more dense in the dentate 
gyrus of the hippocampus, facial nucleus, thalamic and hypothalamic nuclei, with moderate densities found 
in the striatum, cerebellum, dorsal raphe nucleus and locus coeruleus16. 
A report now demonstrates that DMT targets and binds to the S1R with a moderate affinity (KD of 
14.75 µM)17. Though, the KD of DMT at the S1R is approximately 30-fold superior than the highest 
concentrations achieved by intravenous administration, therefore making it very unlikely that endogenous 
DMT could be binding and having a physiological role with these receptors15. 
 
• Trace amine-associated receptor 
Tryptamine is a trace-amine, primary amines that are natural side products of synthesis or metabolism 
of monoamine precursors. Trace amines are found at soft levels within the mammalian/vertebrate brain at 
concentrations approximately 100 times lower than traditional monoamines18. 
TAAR are a family of vertebrate, rhodopsin-like, type A, G protein-coupled receptors. Although 26 
sub- types of TAAR have been identified in mammalian species, they all belong to nine sub-families 
(TAAR1-9). Humans express a single functional variant of 6 of the TAAR family members (TAAR1, 2, 5, 
6, 8 and 9), with TAAR3, 4 and 7 subtypes appearing to be pseudogenes. One of the key challenges in the 
TAAR field is the mostly low receptor expression levels, at least under basal conditions, which necessitates 
the use of the most stringent of reagents and methodologies in order to prevent cross-reactivity1. 
In the rat, highest expression levels of TAAR1 were perceived in the olfactory bulb, nucleus 
accumbens/olfactory tubercle, prefrontal cortex and other cortical regions, midbrain regions consisting of 
substantia nigra and ventral tegmentum, cerebellum, and pons/medulla. Outside of the central nervous 
system, TAAR1 is essentially expressed in pancreatic β-cells, stomach and intestines in human, rat and 
mouse. Recent studies with specific anti-human TAAR1 antibodies, revealed a similar peripheral 
distribution of TAAR1 in human tissues as previously described in mice, with restricted expression in 
pancreatic islets, duodenum and jejunum and pylorus of the stomach19. In addition, several groups have 
reported TAAR1 expression in both human and mouse leukocytes and in human breast cancer tissue. 
However, the commercial anti-TAAR1 antibody used in these studies is not entirely reliable 20. Recent 
research has reported seven rare protein disturbing variants in TAAR1 that could elevate the risk for 
schizophrenia. TAAR1 has also been shown to interact with two other strong candidate genes, namely the 
dopamine transporter (DAT) and DRD2 from the dopaminergic pathway21. 
The binding potency of DMT to TAAR1 compared to its precursor tryptamine, is higher in both rat 
(0.13 µM to 2.2 µM) and mouse (1.4 µM to 3.3 µM). In humans, the E50 value, which indicates how much 
of a drug is needed to achieve 50% of the maximum response, was lower in comparison to tryptamine 20,22, 
suggesting better affinity due to methylation.  
 The role of TAAR receptors is not deciphered yet. TAAR1 appears to function as an endogenous 
rheostat, maintaining central neurotransmission within defined physiological limits, in part through receptor 
heterodimerization yielding biased signaling outputs. TAAR1 knock-out mice have been reported to 
manifest schizophrenia-like behaviors, apparently related with the dopaminergic system23. In addition, pre-
clinical animal models have identified TAAR1 as a novel target for drug addiction and metabolic disorders19. 
Growing evidence also suggests a role for TAARs in regulating immune function and in the central nervous 
system, where it is believed to modulate monoaminergic neurotransmission, thus affecting a number of 
neural networks and processes24,22. 
 
 
State of art about DMT endogenous role 
 
The greatest methodological setback to research in DMT and to its possible binding to the above-
cited receptors is the infimum amount of DMT produced endogenously. Therefore, two theories have arisen 
that try to explain how the concentration of DMT could locally rise. On one hand, it has been suggested that 
DMT could reach high local concentrations in neuron endings through a process involving uptake across the 
plasma membrane, a mechanism identical to those described for known neurotransmitters. The affinity of 
DMT for SERT and vesicular monoamine transporter (vMAT) was investigated and inconsistent results 
point to the existence of affinity, EC50 value of 114 nM to SERT, and vMAT was tested with methodological 
frailties as well. Still, having some affinity for SERT and vMAT is not a leaden argument, as there are more 
compounds that are substrates for the SERT and vMAT for which there is no evidence that they are 
accumulated in vesicles. As Nichols (2017) suggests15, an important experiment that would resolve this 
conflict could be incubating radioactively-labeled DMT with synaptosomes from rats that had been treated 
with a MAO inhibitor. On the other, DMT accumulation in the CNS would be due to the active transport of 
DMT through the blood-brain barrier, but the existing studies reveal important methodological problems and 
non-extrapolated conclusions on brain/plasma ratio of the molecule, which is not a specific proof of active 
transport into the brain15. 
Strassman has suggested that the pineal gland excretes huge quantities of DMT during extremely 
stressful life events, notably birth and death. For this to happen, the pineal gland would need to produce very 
promptly (over seconds) about 25 mg of DMT. The mean daily production of melatonin from the pineal 
gland is approximately 30 µg, about 1/1000 of the weight of DMT needed to get an effect he describes as 
breakthrough into the “DMT space” 11. 
The lack of recent research with more precise methodology has made difficult the elucidation of its 
importance and mechanisms. However, while endogenously the work has not yet reached great 
achievements, research with exogenous DMT has advanced steadily. The interaction of the molecule with 
the above-described receptors may underlie important advances in psychiatric pharmacology. What is 
already known about the therapeutic potential of DMT is described next.  
 
 
 
 
 Therapeutic Potential of N,N-dimethyltryptamine 
 
The therapeutic potential of DMT has been studied mainly in anxiety, depression and substance abuse 
disorders. Here we review the evidence for each of these pathologies. 
 
Anxiety 
 
A case control study with a sample of Santo Daime (religious organization) members reported 
reductions in associated symptomatology of anxiety and depression after a first consumption of Ayahuasca25. 
However, this has been contradicted26. Moreover, these studies were carried out under a religious context, 
which may constitute a biasing factor. 
Studies using rodent models, by ruling out the ceremonial religious aspects, can contribute to 
elucidate the role of the brew per se into the neurobiological mechanisms of ayahuasca on anxiety-related 
behavior. A recent essay in zebrafish suggests that small amounts (0.1, 0.5 mL/L) of ayahuasca do not affect 
locomotion and reduce anxiety-like behavior in zebrafish, while increased doses of the drug lead to crescent 
anxiogenic effects27.  
 
Depression 
 
More recently, two open-label trials conducted by the same group 28,29 evaluated the effects of a 
unique dose of ayahuasca in psychiatric depressive inpatients. In the former, a statistically significant 
reduction of up to 82% was observed in depressive scores in three scales between baseline and 1, 7, and 21 
days after the administration. Furthermore, ayahuasca administration did not produce episodes of mania or 
hypomania, neither did it lead to increases in the thinking disorder subscale. In the latter, the authors reported 
significant decreases in scores on the same depression scales from 80 minutes after administration to day 21. 
Nevertheless, they reported increases in dissociative symptoms. Sanches et al. (2016)29 also included a 
SPECT assessment which describes increased blood perfusion in the left nucleus accumbens, left subgenual 
area and right insula, these are brain regions related to the regulation of mood and emotional states.  
A case control study in 2015 found differences in cortical thickness in regular users of psychedelics. 
Ayahuasca users showed significant cortical thickness differences in midline structures of the brain, with 
thinning in the posterior cingulate cortex, a key node of the default mode network (DMN)10. A case study 
from the same year demonstrated that ayahuasca intake leads to a decrease in the activity of core DMN 
structures as well30. 
Later in 2017 an open-label uncontrolled study in 16 healthy volunteers, ayahuasca consumption 
induced post-acute neurometabolic and connectivity modifications using magnetic resonance 
spectroscopy. The results support the involvement of glutamate neurotransmission in the effects of 
psychedelics in humans. They further rely neurometabolic changes in the posterior cingulate cortex and 
increased connectivity between the anterior cingulate cortex and medial temporal lobe structures involved 
in emotion and memory31. 
These findings are interesting because the resting state brain networks, DMN in particular, have been 
reported to be altered in several psychopathological conditions such as depression and anxiety. 5HT2A 
 agonists can potentially induce structural changes in brain tissue by stimulating neurotrophic and 
transcription factors associated with synaptic plasticity. The functional connectivity of the anterior 
portions of DMN, involved in self-referential and emotional processes, was positively correlated with 
anxiety and depression scores, whereas posterior areas of the DMN, involved in episodic memory and 
perceptual processing were negatively correlated with anxiety and depression scores. The dissociation 
between anterior and posterior cortical midline regions, raises the possibility of a functional specialization 
within the DMN in terms of self-referential tasks and contributes to the understanding of the cognitive and 
affective changes in depressive and anxiety states 32. 
 
Substance Dependence 
  
Observational studies reported remission of alcohol, changes in behavior and perspectives after 
intake of ayahuasca33-35. Fábregas et al. (2010)36 adds that the effects were preserved at one-year follow-up. 
In another case series study, the authors found statistically significant decreases in cocaine use after an 
ayahuasca assisted therapy in a sample with no prior experience with it. Some other descriptive studies, such 
as observational pilot studies and reports of informal interviews, have presented preliminary knowledge 
suggesting a potential beneficial role for ayahuasca in the treatment of substance use disorders 37. 
An investigation with mice was carried out through the development of ethanol-induced behavioral 
sensitization and on a post-sensitization. It revealed that ayahuasca not only inhibits initial behaviors 
associated with the beginning and progress of ethanol addiction, but also showed effectiveness in annulling 
chronic drug effects expression, inhibiting the return of ethanol-induced behavioral sensitization when 
administered in the ethanol-associated environment 38. 
 
Conclusion 
 
Psychedelics are intriguing drugs that induce transient but intense modifications in perception, 
emotion and cognitive processes. While endogenous DMT does not seem to induce remarkable 
modifications, research into DMT as a therapeutic option has proven to be a candidate for the future. The 
incidence of psychotic episodes during ayahuasca ingestion appears to be rare and can be controlled by 
common antipsychotics as quetiapine 39,40. Results indicated that structured ayahuasca consumption was 
medically safe and exhibited a potential protective psychological effect. Most of the psychedelics like 
psilocybin act almost exclusively on the serotonergic system, while DMT has affinities to sigma-1, 
monoaminergic, and trace amine-associated receptors which have some evidence linked with psychiatric 
diseases 30.  An increasing number of papers suggest promising benefits in mood and psychiatric symptoms 
in the areas of substance use disorders, anxiety and depression. DMT is the main compound of ayahuasca 
and its psychedelic effects have been reported as relevant in these clinical areas. However, other known 
compounds of the blend such as harmine and harmaline also revealed anxiolytic effects41. More clinical 
research with the use of pure DMT has to be done to disambiguate the contributions of each substance. The 
most recent studies report a fast and sustained improvement in patients with these diseases, thereby possibly 
opening way for new drugs in the treatment of such common pathologies42, where a lack of solutions43 is 
notable. 
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